A comparative health economic evaluation of venetoclax in combination with obinutuzumab versus Chlorambucil in combination with obinutuzumab as first-line treatment for chronic lymphocytic leukemia in China: a cost-effectiveness analysis
This study demonstrates that, the combination of Ven + Obi as a frontline treatment for CLL is superior to Chl + Obi in terms of cost-effectiveness. Sensitivity analysis indicates that treatment costs will significantly decrease after the patent protection period of these drugs expires.
Authors
- Hanglin Ran
- Xu Yu
- Jiatai Du
- Tianyu Feng
- Zhou Zheng
Institutions
- Jilin University (CN)
- Chongqing Public Health Medical Center (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Cost Effectiveness and Resource Allocation
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1186/s12962-025-00705-w
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00